insights_auto
Why is DRUG down 3,02%?
Dive Deeperchevron_right
DRUG:NASDAQ
Bright Minds Biosciences Inc
54,98 $
arrow_downward
-3,02%(-1,71) 1D
30,00 $
arrow_downward
-45,43% (-24,98)todayPre-market
Closed: 30 հոկ, 15:00:01 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DRUG...
Open
56,90 $
High
57,00 $
Low
54,96 $
Mkt. cap
759,21 մլն
Avg. vol.
135,75 հզր
Volume
100,00
52-wk high
123,75 $
52-wk low
47,35 $
Beta
-5,21
Shares outstanding
9,86 մլն
No. of employees
26
Open
56,90 $
High
57,00 $
Low
54,96 $
Mkt. cap
759,21 մլն
Avg. vol.
135,75 հզր
Volume
100,00
52-wk high
123,75 $
52-wk low
47,35 $
Beta
-5,21
Shares outstanding
9,86 մլն
No. of employees
26
News stories
From web sources and news partners
The Chronicle-Journal
·
56 րոպե առաջ
Marriott (NASDAQ:MAR) exceeds Q3 2026 expectations
TradingView
·
33 րոպե առաջ
US Stocks to Kick Off November Higher
Opening Bell Daily
·
13 րոպե առաջ
S&P 500 sectors in October: tech falls 8.2% as energy jumps
Seeking Alpha
·
1 ժամ առաջ
The Bear Market Is Ending, Not Beginning (SPX)
Profile
Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use.
It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens.
The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York. Wikipedia
About Bright Minds Biosciences Inc